<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01604824</url>
  </required_header>
  <id_info>
    <org_study_id>R727-CL-1018</org_study_id>
    <nct_id>NCT01604824</nct_id>
  </id_info>
  <brief_title>A Study of Alirocumab (REGN727/SAR236553) in Patients With ADH and GOFm of the PCSK9 Gene or LOFm of the apoB Gene</brief_title>
  <official_title>A Phase 2 Pilot Study With a Randomized Double-Blind Treatment Phase to Evaluate the Pharmacodynamics and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia and Gain-of-Function Mutations in 1 or Both Alleles of the PCSK9 Gene or Loss-of-Function Mutations in 1 or More Alleles of the Apolipoprotein B Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacodynamic (PD) effect of alirocumab on serum
      low-density lipoprotein cholesterol (LDL-C) in patients with autosomal dominant
      hypercholesterolemia (ADH) and gain-of-function mutations (GOFm) in 1 or both alleles of the
      proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or with a loss-of-function
      mutation (LOFm) in 1 or more alleles of the apolipoprotein B-100 gene (apoB).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in serum LDL-C</measure>
    <time_frame>day 1 to day 15</time_frame>
    <description>The primary endpoint in the study is the percent change in serum low-density lipoprotein cholesterol (LDL-C) from day 1 (baseline) to day 15.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TEAEs</measure>
    <time_frame>day 1 to day 169</time_frame>
    <description>The incidence and severity of TEAEs reported from the first dose of alirocumab through the last dose of alirocumab in the double-blind treatment period + 70 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEAEs</measure>
    <time_frame>day 1 to week 212 + 70 days</time_frame>
    <description>The incidence and severity of TEAEs reported from the first dose of alirocumab through the last dose of alirocumab in the open-label treatment period (week 212) + 70 days (end-of-study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in ApoB100</measure>
    <time_frame>day 1 to day 15</time_frame>
    <description>Percent change in ApoB100 from day 1 to day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in non-HDL-C</measure>
    <time_frame>day 1 to day 15</time_frame>
    <description>Percent change in non-HDL-C (high-density lipoprotein cholesterol) from day 1 to day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in total cholesterol</measure>
    <time_frame>day 1 to day 15</time_frame>
    <description>Percent change in total cholesterol from day 1 to day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in ApoB100/ApoA1 ratio</measure>
    <time_frame>day 1 to day 15</time_frame>
    <description>Percent change in ApoB100/ApoA1 ratio from day 1 to day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentrations of total alirocumab</measure>
    <time_frame>day 1 through end-of-study</time_frame>
    <description>Trough concentrations of total alirocumab following repeat SC dosing with alirocumab throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of repeat SC dosing</measure>
    <time_frame>day 1 through end-of-study</time_frame>
    <description>Immunogenicity of repeat SC dosing with alirocumab throughout the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: dosing regimen 1; Group B: dosing regimen 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C: dosing regimen 1; Group D: dosing regimen 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alirocumab</intervention_name>
    <description>Randomized, double-blind treatment period may be followed by open-label treatment with alirocumab for all patients if certain criteria are met.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>REGN727</other_name>
    <other_name>SAR236553</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria include, but are not limited to the following:

          1. Between the ages of 18 and 70 years, inclusive

          2. A history of molecularly confirmed PCSK9 GOFm for cohort 1 and a history of
             molecularly confirmed PCSK9 GOFm or ApoB LOFm

          3. Plasma LDL-Cholesterol levels â‰¥70 mg/dL at the screening visit on a lipid lowering
             therapy (LLT) regimen stable for at least 28 days

        Exclusion Criteria:

        Exclusion criteria include, but are not limited to the following:

          1. Serum triglycerides &gt;350 mg/dL at the screening visit

          2. Known to be positive for human immunodeficiency virus (HIV), hepatitis B virus, or
             hepatitis C virus

          3. Pregnant or breast-feeding women.

          4. Sexually active man or woman of childbearing potential who is unwilling to practice
             adequate contraception during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <state>Cedex</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nante</city>
        <state>Cedex</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <disposition_first_submitted>January 24, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>January 24, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 30, 2015</disposition_first_posted>
  <last_update_submitted>January 24, 2015</last_update_submitted>
  <last_update_submitted_qc>January 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 20, 2015</submitted>
    <returned>September 21, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

